|
G |
Gla |
galactosidase, alpha |
|
IMP |
|
RGD |
PMID:29563343 |
RGD:150429980 |
NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664
|
|
G |
Glaem2Mcwi |
galactosidase, alpha; CRISPR/Cas9 system induced mutant 2, Medical College of Wisconsin |
|
IMP |
compared to wild type |
RGD |
PMID:29563343 |
RGD:150429980 |
|
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
|
IAGP |
DNA:mutation:cds: c.2941C>T (rat) |
RGD |
PMID:22634626 |
RGD:13782386 |
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacna1f csnb |
calcium voltage-gated channel subunit alpha1 F; congenital stationary night blindness mutant |
|
IAGP |
DNA:mutation:cds: c.2941C>T (rat) |
RGD |
PMID:22634626 |
RGD:13782386 |
|
|
|
G |
Tmem67 |
transmembrane protein 67 |
|
IAGP |
|
RGD |
PMID:23516626 |
RGD:11535084 |
NCBI chr 5:25,536,458...25,589,378
Ensembl chr 5:25,536,458...25,589,334
|
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
treatment |
IAGP |
|
RGD |
PMID:11592982 |
RGD:69668 |
NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Mertkrdy |
MER proto-oncogene, tyrosine kinase; retinal dystrophy mutant |
treatment |
IAGP |
|
RGD |
PMID:11592982 |
RGD:69668 |
|
|
G |
Myo15a |
myosin XVA |
induces |
IAGP |
DNA:missense mutation:cds:exon 56 T>C, p.Leu3157Pro (rat) compared to LEW/Ztm |
RGD |
PMID:21479269 PMID:21479269 |
RGD:150429616, RGD:150429616 |
NCBI chr10:45,277,619...45,335,953
Ensembl chr10:45,278,737...45,335,340
|
|
G |
Myo15aci2 |
myosin XVA; ci2 mutant |
induces |
IAGP |
compared to LEW/Ztm |
RGD |
PMID:21479269 |
RGD:150429616 |
|
|
G |
Pde6b |
phosphodiesterase 6B |
|
IMP |
compared to wild-type |
RGD |
PMID:31009522 |
RGD:40924664 |
NCBI chr14:1,323,310...1,366,450
Ensembl chr14:1,323,310...1,366,450
|
|
G |
Pde6bem1Baek |
phosphodiesterase 6B; Cpf1-CRISPR induced mutant1, Baek |
|
IMP |
compared to wild-type |
RGD |
PMID:31009522 |
RGD:40924664 |
|
|